B+
Bull case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
ACHV
Achieve Life SciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-06-19 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-19
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+32.6
Score
AI commentary
Recent coverage tone has been mildly constructive because the May 12, 2026 company update paired a large financing with manufacturing-transition progress and commercial buildout, but the setup into June 20, 2026 is still dominated by the expected CRL and resubmission timing rather than by clean operating momentum. Coverage is thin, no reliable post-print analyst revision set is in the packet, and no usable social signal is available, so this remains a monitoring-style setup rather than a high-conviction bullish call.
RankAlpha Sentiment Codex - 2026-06-19
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-20eventJune 20, 2026 FDA action is likely a manufacturing-driven CRL rather than a product-data decisionHigh impact
Management said the prior third-party manufacturer received an OAI classification tied to general cGMP matters not specific to cytisinicline, and Achieve expects a Complete Response Letter on or before the June 20, 2026 PDUFA date, delaying approval but not necessarily changing the core efficacy thesis [#SEC-8K-2026-05-12] [#10-Q-2026-05-12].
2026-11-15catalystQ4 2026 NDA resubmission with Adare is the main re-rating pathHigh impact
Achieve said it intends to resubmit the NDA in Q4 2026 with Adare as the new primary commercial manufacturing partner after completing analytical transfer, first engineering batch work, and testing qualification; successful remediation would be the clearest de-risking step toward the stated H1 2027 U.S. launch plan [#SEC-8K-2026-05-12].
2026-12-31catalystFinancing plus ORCA-V2 funding preserves second-indication optionalityHigh impact
The May 12, 2026 company update said the private placement brought $180.0 million gross, with milestone warrants on approval, and that proceeds are intended to fund commercialization and the ORCA-V2 Phase 3 trial for e-cigarette cessation; that supports runway and keeps the vaping program alive, though it remains secondary to fixing the smoking-cessation NDA path [#SEC-8K-2026-05-12] [#10-Q-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-19 • Updated nightlySource: Internal modelMethodology